Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 3:47 AM
Ignite Modification Date:
2025-12-26 @ 2:35 AM
NCT ID:
NCT02078102
Group ID:
EG001
Title:
Non Hodgkins Lymphoma
Description:
This is for the patients with Non Hodgkins Lymphoma.
Meloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis.
15 mg tablets of Meloxicam will be taken orally for 5 consecutive days.
10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection.
Meloxicam: 15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
Filgrastim: Filgrastim will be subcutaneously injected in one or two sites at home.
Deaths Number Affected:
1
Deaths Number At Risk:
None
Serious Number Affected:
1
Serious Number At Risk:
13
Other Number Affected:
10
Other Number At Risk:
13
Study:
NCT02078102
Results Section:
NCT02078102
Adverse Events Module:
NCT02078102